Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERB-041 in rheumatoid arthritis
NCT00141830Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of prinaberel in rheumatoid arthritis (RA) (4 arms), sponsored by Pfizer. Primary endpoint: American College of Rheumatology 20% improvement criteria at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
prinaberel
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00141830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141830.